< Terug naar vorige pagina
Onderzoeker
Ann Janssens
- Disciplines:Laboratoriumgeneeskunde, Palliatieve zorg en zorg rond het levenseinde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Verpleegkunde, Andere paramedische wetenschappen, Andere translationele wetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Laboratorium voor Experimentele Hematologie (Afdeling)
Lid
Vanaf1 okt 2013 → Heden
Publicaties
1 - 10 van 170
- Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer(2023)
Auteurs: Ann Janssens
Pagina's: 635 - 646 - [F-18]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma(2023)
Auteurs: Vibeke Vergote, Gregor Verhoef, Ann Janssens, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe Deroose
Pagina's: 161 - 170 - Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.(2022)
Auteurs: Ann Janssens
Pagina's: 133 - 143 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations(2022)
Auteurs: Ann Janssens
- Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial(2022)
Auteurs: Ann Janssens
- Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr plus Ven) Versus Chlorambucil Plus Obinutuzumab (Clb plus O): The Glow Study(2022)
Auteurs: Ann Janssens
- Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study(2022)
Auteurs: Ann Janssens
Pagina's: 2333 - 2337 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL(2022)
Auteurs: Ann Janssens
Pagina's: 2772 - 2775 - Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)(2022)
Auteurs: Ann Janssens
- Polyostotic DLBCL Is Characterized By a NF-Kb Pathway Affecting Molecular Profile and Superior Survival(2022)
Auteurs: Ann Janssens
Pagina's: 3534 - 3535